Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:713 (7 April), doi:10.1136/bmj.39174.633403.DB
Susan Mayor
London
| The first 150 words of the full text of this article appear below. |
The risk of death, myocardial infarction, or other major cardiovascular events in patients with stable coronary artery disease is no lower with percutaneous coronary intervention (PCI) than with the optimal therapy of drug treatment with lifestyle intervention, says a major prospective study that is predicted to change practice.
The trial, published online on 26 March in the New England Journal of Medicine (http://content.nejm.org, doi: 10.1056/NEJMoa070829), randomised more than 2000 patients with objective evidence of myocardial ischaemia and significant coronary artery disease to PCI or optimal medical treatment. The results showed no difference in mortality from any cause or in the risk of non-fatal myocardial infarction at a median follow up of 4.6 years.
The findings will change practice, said David Taggart, professor of cardiovascular surgery at Oxford University. "This is a very important trial," he said. "The results reinforce what some of us have believed for some
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses